(Total Views: 430)
Posted On: 03/07/2021 10:39:47 AM
Post# of 153898
This seems very simple to me -
If there was a 24% reduction in mortality in 62 critical patients - .24x62 = 14.88 - or, 15 patients out of 62 survived. .76x62 = 47.12, or 47 critical patients died. There's no way that the trial met its primary endpoint.
I'm not putting much faith in the USFDA, the US government, or Janet Woodcock. I think the likelier path to success is through a foreign government or a groundswell of public opinion here in the USA based most likely upon major media coverage. If the word gets out in a big way that leronlimab is saving lives, the government will have little choice but to make LL available to its citizenry.
If there was a 24% reduction in mortality in 62 critical patients - .24x62 = 14.88 - or, 15 patients out of 62 survived. .76x62 = 47.12, or 47 critical patients died. There's no way that the trial met its primary endpoint.
I'm not putting much faith in the USFDA, the US government, or Janet Woodcock. I think the likelier path to success is through a foreign government or a groundswell of public opinion here in the USA based most likely upon major media coverage. If the word gets out in a big way that leronlimab is saving lives, the government will have little choice but to make LL available to its citizenry.
(2)
(0)
